Present assessment of myocardial viability by nuclear imaging

Seminars in Nuclear Medicine

Volumn 26, Issue 4, 1996, Pages 315-335

  Saha, Gopal B ^a   Maclntyre, William J ^a   Brunken, Richard C ^a   Go, Raymundo T ^a   Raja, Shanker ^a   Oliver Wong, C ^a   Chen, Eric Q ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RUBIDIUM; THALLIUM;

ARTIFACT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEART; HEART MUSCLE; HUMAN; METABOLISM; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ARTIFACTS; DEOXYGLUCOSE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; MYOCARDIUM; RUBIDIUM RADIOISOTOPES; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030256325     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(96)80007-9     Document Type: Article

References (117)

1. American Heart Association: -1990 Heart & Stroke Facts. Dallas, TX, American Heart Association, 1990
2. Ryan TJ, Klocke FJ, Reynolds WA: Clinical competence in percutaneous transluminal coronary angioplasty: A statement for physicians from the ACP/ACC/AHA Task Force on Clinical Privileges in Cardiology. J Am Coll Cardiol 15:1469-1474,1990
3. Opie LH, Tansey M, Kennelly BM: Proposed metabolic vicious circle in patients with large myocardial infarcts and high plasma-free-fatty acid concentration. Lancet 2: 890-892,1977
4. Opie LH: Substrate and energy metabolism of the heart, in Sperelakis N (ed): Physiology and Pathophysiology of the Heart (ed 2). Norwell, MA, Kluwer, 1989
5. Camici P, Ferrannini E, Opie LH: Myocardial metabolism in ischémie heart disease: Basic principles and application to imaging by positron emission tomography. Progr Cardiovasc Dis 32:217-238,1989
6. Newsholme EA: The regulation of phosphofructokinase in muscle. Cardiology 56:22-34,1971
7. Rovetto MJ, Lamberton WF, Neely JR, et al: Mechanism of glycolytic inhibition in ischémie rat hearts. Circulation 37:742-751,1975
8. Gould KL, Yoshida K, Hess MJ, et al: Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET. J Nucl Med 32:1-9, 1991
9. Gehring PJ, Hammond PB: The interrelationship between thallium and potassium in animals. J Pharm Exp Ther 155:187-201,1967
10. Strauss HW, Pitt B: Thallium-201 as a myocardial imaging agent. Semin Nucl Med 7:49-58,1977
11. Skulskii I A, Manninen V, Jarnefelt J: Factors affecting the relative magnitudes of the ouabain-sensitive and ouabain-insensitive fluxes of thallium ion in erythrocytes. Biochem Biophys Acta 506:233-241,1978
12. Pierson RN, Tansey WA, Friedman MI, et al: Cardiovascular nuclear medicine: An overview. Semin Nucl Med 9:224-240,1979
13. Cloninger KG, DePuey EG, Garcia EV, et al: Incomplete redistribution in delayed thallium-201 single photon emission computed tomographic images: An overestimation of myocardial scarring. J Am Coll Cardiol 12:955-963, 1988
14. Kiat H, Berman DS, Maddahi J, et al: Late reversibility of tomographic myocardial thallium-201 defects: An accurate marker of myocardial viability. J Am Coll Cardiol 12:1456-1463,1988
15. Gutman J, Berman DS, Freeman J: Time to complete redistribution of thallium-201 in exercise myocardial scintigraphy: Relationship to the degree of coronary artery stenosis. Am Heart J 106:989-995,1983
16. Angello DA, Wilson RA, Palme RT: Effect of eating on Tl-201 myocardial redistribution after myocardial ischemia. Am J Cardiol 60:528-533,1987
17. Dilsizian V, Rocco TP, Freedman NMT, et al: Enhanced detection of ischémie but viable myocardium by the reinjection of thallium and stress-redistribution imaging. N Engl J Med 323:141-146,1990
18. Dilsizian V, Smeltzer WR, Freedman NMT, et al: Thallium reinjection after stress-redistribution imaging: Does 24 hour delayed imaging following reinjection enhance detection of viable myocardium? Circulation 83: 1247-1255,1991
19. Dilsizian V, Bonow RO: Differential uptake and apparent thallium-201 "wash out" after thallium reinjection: Options regarding early redistribution imaging before reinjection or late redistribution imaging after reinjection. Circulation 85:1032-1038,1992
20. Kiat H, Friedman JD, Wang FP, et al: Frequency of late reversibility in stress-redistribution thallium-201 SPECT using an early reinjection protocol. Am Heart J 122:613-619, 1991
21. Galli M, Marcassa C: Thallium-201 redistribution after early reinjection in patients with severe stress perfusion defects and ventricular dysfunction. Am Heart J 128:41-52,1994
22. van Eck-Smit BLF, van der Wall EE, Kuijper AFM, et al: Immediate thallium reinjection following stress imaging: A time-saving approach for detection of myocardial viability. J Nucl Med 34:737-743,1993
23. Inglese E, Brambilla M, Dondi M, et al: Assessment of myocardial viability after thallium-201 reinjection or rest-redistribution imaging: A multicenter study. J Nucl Med 36:555-563,1995
24. Gewirtz H, Beller GA, Strauss HW, et al: Transient defects of resting thallium scans in patients with coronary artery disease. Circulation 59:707-713,1979
25. Berger BC, Watson DD, Burwell LR, et al: Redistribution of thallium at rest in patients with stable and unstable angina and the effect of coronary artery bypass surgery. Circulation 60:1114-1125,1979
26. Mori T, Minamiji K, Kurogane H, et al: Rest injected thallium-201 imaging for assessing viability of severe asynergic regions. J Nucl Med 32:1718-1724,1991
27. Leppo JA, DePuey EG, Johnson LL: A review of cardiac imaging with sestamibi and teboroxime. J Nucl Med 32:2012-2022,1991
28. Maddahi J, Kiat H, Berman DS, et al: Myocardial perfusion imaging with technetium-99m-labeled agents. Am J Cardiol 67:27D-34D, 1991
29. Wackers FJT, Berman DS, Maddahi J, et al: Technetium-99m hexakis 2-methoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 30:301-311,1989
30. Sinusas AJ, Bergin JD, Edwards NC, et al: Redistribution of ""Tc-sestamibi and 201T1 in the presence of a severe coronary artery stenosis. Circulation 89:2332-2341, 1994
31. Li QS, Solot G, Frank TL, et al: Myocardial redistribution of technetium-99m-methoxyisobutyl isonitrile (sestamibi). J Nucl Med 31:1069-1076,1990
32. Villanueva-Meyer J, Mena I, Diggles L, et al: Assessment of myocardial perfusion defect size after early and delayed SPECT imaging with technetium-99m-hexakis 2methoxyisobutyl isonitrile after stress. J Nucl Med 34:187193,1993
33. Maurea S, Cuocolo A, Soricelli A, et al: Myocardial viability index in chronic coronary artery disease: technetium-99m-methoxy isobutyl isonitrile redistribution. J Nucl Med 36:1953-1960,1995
34. Richter WS, Cordes M, Calder D, et al: Washout and redistribution between immediate and two-hour myocardial images using technetium-99m sestamibi. Eur J Nucl Med 22:49-55,1995
35. Taillefer R, Dupras G, Sporn V, et al: Myocardial perfusion imaging with a new radiotracer technetium-99mhexamibi (methoxyisobutyl-isonitrile): Comparison with thallium-201 imaging. Clin Nucl Med 14:89-96,1989
36. 99mTc-hexakis-2-methoxy-2-methylpro-pyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 80:1277-1286,1989
37. Rocco TP, Dilsizian V, Strauss HW, et al: Technetium-99m isonitrile myocardial uptake at rest. II Relation to clinical markers of potential viability. J Am Coll Cardiol 14:1678-1684,1989
38. Marzullo P, Sambuceti G, Parodi O: The role of sestamibi scintigraphy in the radioisotopic assessment of myocardial viability. J Nucl Med 33:1925-1930,1992
39. Freeman I, Grunwald AM, Hoory S, et al: Effect of coronary occlusion and myocardial viability on myocardial activity of technetium-99m-sestamibi. J Nucl Med 32:292-298,1991
40. Beanlands RSB, Dawood F, Wen WH, et al: Are the kinetics of technetium-99m methoxy-isobutyl isonitrile affected by cell metabolism and viability? Circulation 82: 1802-1814,1990
41. Maublant JC, Citron B, Lipiecki J, et al: Rest technetium 99m-sestamibi tomoscintigraphy in hibernating myocardium. Am Heart J 129:306-314,1995
42. Herman DS, Kiat H, Friedman J, et al: Separate acquisition rest thallium-201 stress Tc-99m sestamibi dual isotope myocardial perfusion SPECT: A clinical validation study. J Am Coll Cardiol 22:1455-1464,1993
43. Berman DS, Kiat HS, Van Train KF, et al: Myocardial perfusion imaging with technetium-99m-sestamibi: Comparative analysis of available imaging protocols. J Nucl Med 35:681-688,1994
44. Feinendegen LE, Vyska K, Freundlieb CH, et al: Non-invasive analysis of metabolic reactions in body tissues in the case of myocardial fatty acids. Eur J Nucl Med 6:191-200,1981
45. Dudczak R, Kletter K, Friochauf H, et al: The use of I-123-labeled heptadecanoic acid (HDA) as metabolic tracer: Preliminary report. Eur J Nucl Med 9:81-85,1985
46. Fridrich L, Pichler M, Gassner A, et al: Tracer elimination of 1-123 heptadecanoic acid: Half-life, component ratio, and circumferential washout profiles in patients with cardiac disease. Eur Heart J 6:61-70,1985 (suppl B)
47. Machulla HJ, Dutschka K, Van Beuningen D: Development of 15-(p-I-123-phenyl)-pentadecanoic acid for in vivo diagnosis of the myocardium. J Radioanalyt Chem 65:279-286,1981
48. Hansen CL, Corbett JR, Pippin JJ, et al: I-123 phenylpentadecanoic acid and single photon emission computed tomography in identifying left ventricular regional metabolic abnormalities in patients with coronary artery disease: Comparison with Tl-201 myocardial tomography. Am J Coll Cardiol 12:78-87,1988
49. Reske SN: I-123-phenylpentadecanoic acid as a tracer of cardiac free fatty acid metabolism: Experimental and clinical results. Eur Heart J 6:39-47,1985 (suppl B)
50. Murray G, Schad N, Ladd W, et al: Metabolic cardiac imaging in severe coronary disease: assessment of viability with iodine-123-iodophenylpentadecanoic acid and multicrystal gamma camera and correlation with biopsy. J Nucl Med 33:1269-1277,1992
51. Dudczak R, Schmoliner R, Angelberger P, et al: Structurally modified fatty acids: Clinical potential as tracers of metabolism. Eur J Nucl Med 12:45-48,1986
52. Tamaki N, Kawamoto M, Yonekura Y, et al: Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 33:659-667,1992
53. Knapp FF Jr, Franken P, Kopp J: Cardiac SPECT with iodine-123-labeled fatty acids: Evaluation of myocardial viability with BMIPP. J Nucl Med 36:1022-1030,1995
54. Stoll HP, Hellwig N, Alexander C, et al: Myocardial metabolic imaging by means of fluorine-18 deoxyglucose/ technetium-99m sestamibi dual-isotope single-photon emission tomography. Eur J Nucl Med 21:1085-1093,1994
55. Burt RW, Perkins OW, Oppenheim BE, et al: Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 36:176-179,1995
56. Martin WH, Delbeke D, Patton JA, et al: FDGSPECT: Correlation with FDG-PET. J Nucl Med 36: 988-995,1995
57. Delbeke D, Videlefsky S, Patton JA, et al: Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99mMIBI/fluorine-18-FDG. J Nucl Med 36:2110-2119,1995
58. Goldstein RA, Mullani NA, Wong WH, et al: Positron imaging of myocardial infarction with rubidium-82. J Nucl Med 27:1824-1829,1986
59. Gould KL, Goldstein RA, Mullani NA, et al: Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologie coronary vasodilatation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82. J Am Coll Cardiol 7:775-789,1986
60. Go RT, Marwick TH, Maclntyre WJ, et al: A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging using a single dipyridamole stress in the diagnosis of coronary artery disease. J Nucl Med 31:1899-1905,1990
61. vom Dahl J, Muzik O, Wolfe ER, et al: Myocardial Rb-82 tissue kinetics assessed by dynamic positron emission tomography as a marker of myocardial cell membrane integrity and viability. Circulation 93:238-245,1996
62. Tillisch J, Brunken RC, Marshall R, et al: Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314:884-888,1986
63. Tamaki N, Yonekura Y, Yamashita K, et al: Positron emission tomography using fluorine-18-deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 64:860-865,1989
64. Marwick TH, Nemec JJ, Lafont A, et al: Prediction of post-exercise fluor-18-deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 69:854-859,1992
65. Neely JR, Morgan JE: Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 36:413-459,1974
66. Leidtke AJ: Alterations of carbohydrate and lipid metabolism in the acutely ischémie heart. Prog Cardiovasc Dis 23:312-336,1981
67. Lerch RA, Ambos HD, Bergmann SR, et al: Localization of viable ischémie myocardium by positron emission tomography with "C-palmitate. Circulation 64:689-699,1981
68. Ter-Pogossian MM, Klein MS, Markham J, et al: Regional assessment of myocardial metabolic integrity in vivo by positron emission tomography with C-ll palmitate. Circulation 61:242-255,1980
69. Brown MA, Marshall DR, Sobel BE, et al: Delineation of myocardial oxygen utilization with carbon-11acetate. Circulation 76:687-696,1987
70. Gropler RJ, Siegel BA, Sampathkumaran KS, et al: The dependence of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. J Am Coll Cardiol 19:989-997,1992
71. Bergmann SR: Use and limitations of tracers labeled with positron-emitting radionuclides in the identification of viable myocardium. J Nucl Med 35:15S-22S, 1994 (suppl)
72. Henes CG, Bergman SR, Walsh MN, et al: Assessment of myocardial oxidative metabolic reserve with positron emission tomography and carbon-11 acetate. J Nucl Med 30:1489-1499,1989
73. Walsh MN, Geltman EM, Brown MA, et al: Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11-acetate in patients with myocardial infarction. J Nucl Med 30: 1789-1808,1989
74. Cuocolo A, Maurea S, Pace L, et al: Resting technetium-99m methoxyisobutylisonitrile cardiac imaging in chronic artery disease: comparison with rest-distribution thallium-201 scintigraphy. Eur J Nucl Med 20:1186-1192, 1993
75. Maurea S, Cuocolo A, Pace L, et al: Rest-injected thallium-201 redistribution and resting technetium-99m methoxyisobutyl-isonitrile uptake in coronary artery disease: Relation to the severity of coronary artery stenosis. Eur J Nucl Med 20:502-510,1993
76. Udelson JE, Coleman PS, Metherall J, et al: Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 4'Tl and "Tcsestamibi. Circulation 89:2552-2561,1994
77. Van Train KF, Garcia EV, Maddahi J, et al: Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m-sestamibi myocardial tomograms. J Nucl Med 35:609-618,1994
78. Reske SN, Biersack HJ, Lackner K, et al: Assessment of regional myocardial uptake and metabolism of o>-(p-123Iphenyl-)pentadecanoic acid with single-photon emission tomography. J Nucl Med 6:249-253,1982
79. Henrich MM, Vester E, von der Lohe E, et al: The comparison of 2-18F-2-deoxyglucose and 15-(ortho-123Iphenyl)-pentadecanoic acid uptake in persisting defects on thallium-201 tomography in myocardial infarction. J Nucl Med 2:1353-1357,1991
80. Brunken RC, Schwaiger M, Grover-McKay M, et al: Positron emission tomography detects tissue metabolic activity in myocardial segment with persistent thallium perfusion defects. J Am Coll Cardiol 10:557-567,1987
81. Brunken RC, Kottou S, Nienaber ÇA, et al: PET detection of viable tissue in myocardial segments with persistent defects at Tl-201 SPECT. Radiology 172:65-73, 1989
82. Tamaki N, Yonekura Y, Yamashita K, et al: Relationship of left ventricular perfusion and wall motion with metabolic activity in persistent defects on thallium-201 tomography in healed myocardial infarction. Am J Cardiol 62:202-208,1988
83. Tamaki N, Yonekura Y, Yamashita K, et al: SPECT thallium-201 tomography and positron tomography using N-13 ammonia and F-18-fluorodeoxyglucose in coronary artery disease. Am J Cardiac Imaging 3:3-9,1989
84. Bonow RO, Dilsizian V, Cuocolo A, et al: Identification of viable myocardium in patients with coronary artery disease and left ventricular dysfunction: Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 83:26-37,1991
85. Tamaki N, Ohtani H, Yamashita K, et al: Metabolic activity in the areas of new fill-in after thallium-201 reinjection: Comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 32:673-678,1991
86. Knuuti MJ, Saraste M, Nuurila P, et al: Myocardial viability: Fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 127:785-786,1994
87. Altehoefer C, vom Dahl J, Buell U, et al: Comparison of thallium-201 single photon emission tomography after rest injection and fluorodeoxyglucose positron emission tomography for assessment of myocardial viability in patients with chronic coronary artery disease. Eur J Nucl Med 21:37-45,1994
88. Perrone-Filardi P, Bacharach SL, Dilsizian V, et al: Clinical significance of reduced regional myocardial glucose uptake in regions with normal blood flow in patients with chronic coronary artery disease. J Am Coll Cardiol 23: 608-618,1994
89. Lucignani G, Paolini G, Landoni C, et al: Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxyD-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 19:874-881,1992
90. Altehoefer C, Kaiser HJ, Dorr R, et al: Fluorine-18 deoxyglucose PET for assessment of viable myocardium in perfusion defects in """Tc-MIBI SPECT: A comparative study with coronary artery disease. Eur J Nucl Med 19: 334-342,1992
91. Altehoefer C, vom Dahl J, Biedermann M, et al: Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: Comparison with fluorine-18-FDG PET. J Nucl Med 35:569-574, 1994
92. Dilsizian V, Arrighi JA, Diodati JG, et al: Myocardial viability with chronic artery disease. Comparison of 99mTcsestamibi with thallium reinjection and [18F]Fluorodeoxyglucose. Circulation 89:578-587,1994
93. Sawada SG, Allman KC, Muzik O, et al: Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 23: 92-98,1994
94. Hicks RJ, Herman WH, Kalff V, et al: Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol 18:101-111,1991
95. Gropler RJ, Geltman EM, Sampathkumaran KS, et al: Functional recovery after revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 20:569-577,1992
96. Gropler RJ, Geltman EM, Sampathkumaran KS, et al: Comparison of carbon-11-acetäte with fluorine-18fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 22: 1587-1597,1993
97. Tamaki N, Yonekura Y, Konishi J: Myocardial FDG PET studies with the fasting, oral glucose-loading or insulin clamp methods. J Nucl Med 33:1263-1268,1992
98. Gropler RJ, Siegel BA, Lee KJ, et al: Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med 31:1749-1756, 1990
99. Beri JJ, Baker JA, Pieper KS, et al: The effect of metabolic milieu on cardiac PET imaging using fluorine-18deoxyglucose and nitrogen-13 ammonia in normal volunteers. J Nucl Med 32:1518-1525,1991
100. Knuuti MJ, Nuutila P, Ruotsalainen U, et al: Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med -33:1255-1262,1992
101. Bianco JA, Bakanauskas J, Carlson M, et al: Augmented uptake of -2-C-14-D-deoxyglucose in reversely injured myocardium. Bur J Nucl Med 13:557-562,1988
102. Wijns W, Jaque AM, Leners N, et al: Accumulation of polymorphonuclear leukocytes in reperfused ischémie canine myocardium: Relation with tissue viability assessed by fluorine-18-2-deoxyglucose uptake. J Nucl Med 29: 1826-1832,1988
103. Buxton DB, Vaghaiwalla-Mody F, Krivokapich J, et al: Quantitative measurement of sustained metabolic abnormalities in reperfused canine myocardium. J Nucl Med -31:795,1990 (abstr)
104. Schelbert HR, Ashburn WL, Chauncey DM, et al: Comparative myocardial uptake of intravenously administered radionuclides. J Nucl Med -15:1092-1100,1974
105. + activity in swine. Circulation -61:768-778,1980
106. Mousa SA, Maina M, Brown BA, et al: Retention of RP-30 in the heart may be due to binding to a cytosolic protein. J Nucl Med 28:619P, 1987 (abstr)
107. Mousa SA, Cooney JM, Williams SJ, et al: Regional myocardial distribution of RP-30 in animal models of myocardial ischemia and reperfusion. J Nucl Med 28:620P, 1987 (abstr)
108. Mousa SA, Williams SJ, Sands H: Characterization of in vivo chemistry of cations in the heart. J Nucl Med -28:1351-1357,1987
109. Anagnostopoulos C, Laney R, Pennell D, et al: A comparison of resting images from two myocardial tracers. Eur J Nucl Med -22:1029-1034,1995
110. Bisi G, Sciagra R, Santoro GM, et al: Technetium-99m-sestamibi imaging with nitrate infusion to detect viable hibernating myocardium and predict post revascularization recovery. J Nucl Med 36:1994-2000,1995
111. Maurea S, Cuocolo A, Soricelli A, et al: Enhanced detection of viable myocardium by technetium-99m-MIBI after nitrate administration in chronic artery disease. J Nucl Med 36:1945-1952,1995
112. Heo J, Kegel J, Iskandrian AS, et al: Comparison of same-day protocols using technetium-99m-sestamibi myocardial imaging. J Nucl Med -33:186-191,1992
113. Schoeder H, Friedrich M, Topp H: Myocardial viability: what do we need? Eur J Nucl Med -20:792-803, 1993
114. Eitzman D, Al-Aouar Z, Kanter HL, et al: Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol -20:559-565,1992
115. Di Carli MF, Davidson M, Little R, et al: Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol -73:527-533,1994
116. Machac J: Technetium-99m isonitrile: A perfusion or viability agent. J Am Coll Cardiol 14:1685-1688,1989
117. Goldhaber SZ, Newell JB, Alpert NM, et al: Effects of ischemic-like insult on myocardial thallium-201 accumulation. Circulation 67:778-786,1983